Navigation Links
Cell Therapeutics Announces Sale of Convertible Preferred Stock
Date:9/12/2013

f risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities.  Such statements include, but are not limited to, statements regarding CTI's expectations with respect to the completion and timing of its proposed Offering and use of proceeds from the Offering.  Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed Offering; risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the outcome of preclinical and clinical studies, that CTI may not obtain reimbursement for PIXUVRI in certain markets in the European Union as planned, that the conditional marketing authorization for PIXUVRI may not be renewed, that the second Phase 3 clinical trial of pacritinib will not occur as planned, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities, that CTI may experience delays in the commencement of preclinical and clinical studies, risks related to the costs of developing, producing and selling PIXUVRI, pacritinib, and CTI's other product candidates, and other risks, including, without limitation, competitive factors, technological developments, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI may not achieve previously announced goals and objectives as or when projected, that CTI's average net operating burn rate may increase, that CTI will contin
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BGI Tech and South Texas Accelerated Research Therapeutics Initiate Collaboration to Advance Unique San Antonio 1000 Cancer Genome Project
2. Breckenridge Completes Acquisition of Certain Cypress Products from Pernix Therapeutics
3. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
4. Sorrento Therapeutics Completes IgDraSol Merger
5. MicroConstants China In-licenses Phase 2 Liver Cancer Drug from Canadian Pertinax Therapeutics
6. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
7. Sorrento Therapeutics to Present at Two Healthcare Conferences
8. Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
9. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
10. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
11. NaZura BioHealth Spun-out from Elcelyx Therapeutics to Advance Lovidia for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... regarding the notice it received on May 21, 2015 ... the Company was below certain of the Exchange,s continued ... 1101 of the NYSE MKT Company Guide, due to ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Cepheid (NASDAQ: CPHD) ... Officer, received the Ernst & Young Entrepreneur Of The ... category. According to Ernst & Young LLP, the award ... in such areas as innovation, financial performance and personal ...
... 28, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: ... Russell 3000®, Russell 2000® and Russell Global Indexes posted by ...   Annual reconstitution of Russell,s U.S. indexes captures ... May, ranking them by total market capitalization. Membership in the ...
Cached Medicine Technology:Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner 2Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner 3Cell Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes 2Cell Therapeutics Added to Russell 3000®, Russell 2000® and Russell Global Indexes 3
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating ... Lines ." It's for women interested in improving their love lives using specific ... which officially launched to the public early this morning, has drawn praise from ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth ... 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 in ...
(Date:7/30/2015)... County, CA (PRWEB) , ... July 30, 2015 , ... ... County, Los Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare ... new rating system of home health care providers. 24/7 Care At Home’s agency is ...
(Date:7/30/2015)... Melbourne, FL (PRWEB) , ... July 30, 2015 , ... ... Central Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This ... years, Dr. Clevens has worked closely with the university, developing a strong presence and ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health ... 2015 Special Olympics World Games, the largest sports and humanitarian event in the world ... Games. , The World Games, held July 25 through August 2, 2015, benefited from ...
Breaking Medicine News(10 mins):Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3
... The E2F family of genes is thought to play a ... these genes carry out their function and interact with one ... repressor genes are essential for a functional placenta and for ... COLUMBUS, Ohio Two particular repressor genes in a family ...
... halting cancer progression by exploiting a previously unrecognized "addiction" ... published by Cell Press online on April 16th in ... critical for tumor development and survival, and describes a ... Many cancers are associated with the loss of ...
... April 15 (HealthDay News) -- Genes that increase or reduce ... been identified by an international team of scientists. ... genes that may explain individual differences in brain size and ... senior author Paul Thompson, a professor of neurology at the ...
... 16 (HealthDay News) -- Large differences exist in the levels ... the United States and other developed countries, a new study ... 2,100 food items in seven product categories sold by Burger ... Subway in the United States, Canada, Australia, France, New Zealand ...
... full-contact football appear to be rising, especially among high ... The increase is alarming and indicates more coaches and ... skills of the game, according to researchers based at ... Until recently, the number of football-related brain injuries with ...
... will share the latest clinical research with addiction ... during the April 19th Blending Conference in Atlanta, ... Institute on Drug Abuse (NIDA), part of the ... American Society of Addiction Medicine Annual Medical-Scientific Conference ...
Cached Medicine News:Health News:2 repressor genes identified as essential for placental development 2Health News:Therapy exploits 'addiction' of leukemia cells 2Health News:Researchers ID Genes That May Determine Mental Illness 2Health News:Fast Food Is Saltier in U.S. Than Overseas 2Health News:Football-related catastrophic brain injuries on the rise 2Health News:Football-related catastrophic brain injuries on the rise 3
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... system uses prolene as thread-guide reducing time and ... Probe is inserted into the nasolacrimal duct and ... The probe is then withdrawn leaving the polypropylene ... diam silicone tubing into place. Newly coated with ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... conforms to natural anatomy of the ... on disposable inserter/dilator instrument for ease ... The Micro-Large plugs feature the unique ... shape of the eyelid. The slightly ...
Medicine Products: